Pre­clin­i­cal can­cer biotech IGM Bio­sciences sets stage for up­sized $175M IPO

Flush with cash from a $102 mil­lion round in Ju­ly, pre­clin­i­cal biotech IGM Bio­sciences and its en­riched squad of can­cer-fo­cused an­ti­bod­ies are scur­ry­ing on­to an up­sized Nas­daq de­but.

The Moun­tain View, Cal­i­for­nia-based com­pa­ny in Au­gust un­veiled plans for a $100 mil­lion IPO — on Tues­day it dis­closed it had raised $175 mil­lion by sell­ing about 10.9 mil­lion shares for $16/share. It will be­gin trad­ing un­der the sym­bol “IGMS” on Wednes­day.

The biotech­nol­o­gy com­pa­ny’s ar­se­nal of ther­a­pies-in-de­vel­op­ment are based on en­gi­neered IgM an­ti­bod­ies to com­bat can­cer — carv­ing it­self a niche from the swathes of drug­mak­ers who have har­nessed the po­ten­tial of IgG an­ti­bod­ies to de­vel­op on­col­o­gy treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER